Cencora, Inc. (NYSE:COR) Receives $275.60 Average PT from Analysts

Cencora, Inc. (NYSE:COR - Get Free Report) has received an average rating of "Moderate Buy" from the eleven ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $275.60.

A number of research firms have recently weighed in on COR. Bank of America reaffirmed a "neutral" rating and issued a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Wells Fargo & Company cut their price objective on shares of Cencora from $249.00 to $237.00 and set an "equal weight" rating on the stock in a report on Friday, December 13th. Mizuho assumed coverage on shares of Cencora in a report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 target price for the company. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research note on Thursday, November 7th. Finally, Leerink Partners lowered their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research note on Monday, October 7th.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now owns 326,557 shares of the company's stock, valued at $79,670,111.29. This represents a 13.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,696 shares of company stock worth $22,862,734. Company insiders own 15.80% of the company's stock.

Institutional Investors Weigh In On Cencora

Hedge funds and other institutional investors have recently modified their holdings of the stock. Flywheel Private Wealth LLC bought a new stake in Cencora during the fourth quarter valued at about $223,000. Carolina Wealth Advisors LLC grew its stake in shares of Cencora by 270.3% during the 4th quarter. Carolina Wealth Advisors LLC now owns 985 shares of the company's stock valued at $221,000 after acquiring an additional 719 shares during the period. Redhawk Wealth Advisors Inc. grew its stake in shares of Cencora by 8.1% during the 4th quarter. Redhawk Wealth Advisors Inc. now owns 11,292 shares of the company's stock valued at $2,537,000 after acquiring an additional 848 shares during the period. Thurston Springer Miller Herd & Titak Inc. increased its holdings in Cencora by 71.1% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 7,048 shares of the company's stock worth $1,583,000 after acquiring an additional 2,928 shares in the last quarter. Finally, Park Avenue Securities LLC raised its stake in Cencora by 37.0% during the 4th quarter. Park Avenue Securities LLC now owns 11,690 shares of the company's stock worth $2,627,000 after acquiring an additional 3,156 shares during the period. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Up 1.8 %

Cencora stock traded up $4.27 during trading hours on Tuesday, hitting $240.36. 1,377,008 shares of the stock traded hands, compared to its average volume of 1,317,676. Cencora has a one year low of $214.77 and a one year high of $253.27. The company has a market cap of $46.46 billion, a PE ratio of 32.01, a PEG ratio of 1.54 and a beta of 0.49. The firm's 50-day moving average price is $237.95 and its two-hundred day moving average price is $233.65. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.92%. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora's dividend payout ratio (DPR) is presently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.